Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy

Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis are quite different between Japanese guideline (JSCCR) and western countries' guideline (NCCN, ESMO). While Japanese scholars advocate total mesorectal excision (TME) plus lateral lymph node dissection (LLND), European and American scholars advocate TME alone after Neoadjuvant Chemo-radiotherapy (nCRT), without the need of LLND. Accordingly, this clinical trial is designed to directly compare the efficacy and safety of these two treatment strategies for low rectal cancer with regional lymph node metasta

Trial Details

NCT ID

NCT03587480

Phase

NA

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• TME+LLND
• TME+nCRT

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Histologically confirmed adenocarcinoma(below the peritoneal reflection) Clinical stage Ⅲ
• Tumor is capable of performing radical recession
• No past history of chemotherapy, pelvic radiation of other cancers.
• Written informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →